Valeant Nets CRL Over GMP Deficiencies

Drug Industry Daily
A A
Valeant Pharmaceuticals’ application for a latanoprostene bunod eye solution was rejected by the FDA amid concerns about conditions at the company’s manufacturing facilities.

To View This Article:

Login

Subscribe To Drug Industry Daily